Elliot, great timing on this post. Really enjoyed learning about Vial. This high throughput model for drug discovery/development/and testing is awesome. Going full stack is truly the only way to turn the dogmatic nature of this industry on its head. I could almost see Vial becoming the infrastructure layer for "fabless" pharma and techbio companies. First vertically integrate like amazon and then start offering AWS etc.
Have you heard of Novartis's data42 initiative? I would love for your to explore some ways that big pharma companies are attempting to become more tech native. Looking forward to more posts as always!
Hey Elliot! As we delve into the exciting frontier of biology, your insightful article on Vial's vision truly sparks my interest. With innovative minds like yours and the advancements in AI-first platforms, I'm optimistic about the transformative potential of clinical trials. Looking forward to more fascinating reads from you!
Thank you for writing this Elliot! So excited to follow Vial -- one of those areas when you think about it, it’s so obvious we should attack with first principles and tech, and yet it doesn’t seem to have happened.
Having worked in a CRO, I agree there’s a lot of “waste”. However I would still point it back to the regulators EMA and FDA that has built up this industry. Almost all the clients know that there are unavoidable costs in order to get a biologic past the gatekeepers
Elliot, great timing on this post. Really enjoyed learning about Vial. This high throughput model for drug discovery/development/and testing is awesome. Going full stack is truly the only way to turn the dogmatic nature of this industry on its head. I could almost see Vial becoming the infrastructure layer for "fabless" pharma and techbio companies. First vertically integrate like amazon and then start offering AWS etc.
Have you heard of Novartis's data42 initiative? I would love for your to explore some ways that big pharma companies are attempting to become more tech native. Looking forward to more posts as always!
Hey Elliot! As we delve into the exciting frontier of biology, your insightful article on Vial's vision truly sparks my interest. With innovative minds like yours and the advancements in AI-first platforms, I'm optimistic about the transformative potential of clinical trials. Looking forward to more fascinating reads from you!
Thank you for writing this Elliot! So excited to follow Vial -- one of those areas when you think about it, it’s so obvious we should attack with first principles and tech, and yet it doesn’t seem to have happened.
Superb article, Elliot!
Thanks Elliot for another banger of an article! 🧠
Having worked in a CRO, I agree there’s a lot of “waste”. However I would still point it back to the regulators EMA and FDA that has built up this industry. Almost all the clients know that there are unavoidable costs in order to get a biologic past the gatekeepers